EI
PTGX icon

EFG International’s Protagonist Therapeutics PTGX Stock Holding History

EFG International’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.96M Sell
40,501
-9,585
-19% -$1M 0.09% 196
2026
Q1 		$5.28M Sell
50,086
-22,537
-31% -$2M 0.11% 165
2025
Q4 		$6.34M Buy
+72,623
New +$5.94M 0.12% 140

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

EFG International's PTGX Position: Q2 2026 in Review

EFG International reduced its Protagonist Therapeutics (PTGX) stake by 19% in Q2 2026, selling an estimated $1M and leaving 40,501 shares worth $4.96M. The position accounts for 0.09% of the portfolio, ranked #196.

EFG International first reported a position in PTGX in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.34M in Q4 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • EFG International held 40,501 shares of Protagonist Therapeutics worth $4.96M as of Q2 2026.
  • EFG International sold 9,585 Protagonist Therapeutics shares in Q2 2026, an estimated $1M.
  • Protagonist Therapeutics made up 0.09% of EFG International's portfolio in Q2 2026, its #196 holding.
  • EFG International first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • EFG International's Protagonist Therapeutics position peaked at $6.34M in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on EFG International's 13F filing for Q2 2026, filed 14 Aug 2026.